This is What Merck & Co. (MRK) is Doing to Mitigate Against KEYTRUDA Exclusivity Loss

Merck & Co., Inc. (NYSE:MRK) is one of Goldman Sachs apical healthcare stocks. On March 3 astatine the TD Cowen 46th Annual Health Care Conference, Merck & Co., Inc. (NYSE:MRK) unveiled strategical initiatives to mitigate the nonaccomplishment of exclusivity of its blockbuster drug, KEYTRUDA. The institution expects a shallow dip successful revenues from the flagship cause arsenic its exclusivity ends.

The strategical initiatives absorption connected innovation to alteration the existent portfolio done caller products. The institution is already expanding its oncology pipeline portion besides exploring caller attraction options successful cardiovascular and different therapeutic areas. Some of the caller products slated for motorboat see WINREVAIR, OHTUVAYRE, CAPVAXIVE, INFLUENZA, and QULEX.

MK-1406 objective trials for influenza prevention are ongoing successful the Southern Hemisphere, portion V940, a neoantigen therapy, is nether development, with a melanoma readout expected successful 2028. It is besides moving connected MK-3000, which targets patients with diabetic macular edema and neovascular AMD.

Merck is besides processing implicit 20 caller maturation drivers successful the quality wellness concern arsenic it targets $70 cardinal successful commercialized opportunity. The institution is besides pursuing strategical concern improvement to treble carnal wellness gross by mid-2030.

Merck & Co., Inc. (NYSE:MRK) is simply a leading, research-intensive planetary biopharmaceutical institution that discovers, develops, and manufactures medicine medicines, vaccines, and biologic therapies. It specializes successful quality health—particularly oncology, infectious diseases, and immunology—while besides providing carnal wellness products.

While we admit the imaginable of MRK arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Affordable Growth Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey connected Google News.